These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 34248473)

  • 1. Ribociclib-Induced Pneumonitis: A Case Report.
    Algwaiz G; Badran AA; Elshenawy MA; Al-Tweigeri T
    Breast Care (Basel); 2021 Jun; 16(3):307-311. PubMed ID: 34248473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.
    Rascon K; Flajc G; De Angelis C; Liu X; Trivedi MV; Ekinci E
    Ann Pharmacother; 2019 May; 53(5):501-509. PubMed ID: 30522347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM; Zangardi ML; Moy B; Bardia A
    Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ribociclib-induced visual hallucination in a patient with metastatic breast cancer.
    Kapagan T; Bulut N; Demirer S; Erdem GU
    J Oncol Pharm Pract; 2023 Sep; 29(6):1529-1532. PubMed ID: 37306182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ
    Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribociclib plus fulvestrant in the treatment of breast cancer.
    Neven P; Sonke GS; Jerusalem G
    Expert Rev Anticancer Ther; 2021 Jan; 21(1):93-106. PubMed ID: 33085548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribociclib-induced pulmonary infiltrates in a patient with breast cancer.
    Ünsal O; Özet A
    J Oncol Pharm Pract; 2023 Sep; 29(6):1537-1540. PubMed ID: 37524106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
    Ramos-Esquivel A; Hernández-Steller H; Savard MF; Landaverde DU
    Breast Cancer; 2018 Jul; 25(4):479-488. PubMed ID: 29470723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
    Abraham J; Coleman R; Elias A; Holmes FA; Kalinsky K; Kittaneh M; Lower E; Mahtani R; Terry Mamounas E; Pegram M; Vogel C;
    Breast Cancer Res Treat; 2018 Aug; 171(1):11-20. PubMed ID: 29725889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polypharmacy and drug-drug interactions in metastatic breast cancer patients receiving cyclin-dependent kinase (CDK) 4/6 inhibitors.
    Kapagan T; Bulut N; Erdem GU
    J Oncol Pharm Pract; 2023 Dec; ():10781552231218959. PubMed ID: 38073115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection.
    Parati MC; Pedersini R; Perego G; Reduzzi R; Savio T; Cabiddu M; Borgonovo K; Ghilardi M; Luciani A; Petrelli F
    Breast Cancer (Dove Med Press); 2022; 14():101-111. PubMed ID: 35440873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer.
    Curigliano G; Criscitiello C; Esposito A; Intra M; Minucci S
    Expert Opin Drug Metab Toxicol; 2017 May; 13(5):575-581. PubMed ID: 28395543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitiligo-like lesions associated with ribociclib in a woman with metastatic breast cancer.
    Türkel A; Karaçin C; Öner İ; Şeyran E; Öksüzoğlu B
    J Oncol Pharm Pract; 2023 Feb; ():10781552231156521. PubMed ID: 36760158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
    Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
    Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study.
    Yıldırım HÇ; Mutlu E; Chalabiyev E; Özen M; Keskinkılıç M; Ön S; Çelebi A; Dursun B; Acar Ö; Kahraman S; Aykan MB; Kaman Ö; Doğan A; Erdoğan AP; Melisa Celayir Ö; Günenç D; Güven DC; Vedat Bayoğlu İ; Yavuzşen T; Hacıbekiroğlu İ; İnanç M; Kılıçkap S; Yalçın Ş; Aksoy S
    Breast; 2022 Dec; 66():85-88. PubMed ID: 36208540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
    Burris HA
    Expert Rev Anticancer Ther; 2018 Mar; 18(3):201-213. PubMed ID: 29457921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDK 4/6 inhibitor induced lung injury: a case report and review of literature.
    Mathew N; Joel A; Andrews AG; John AO; Singh A
    Ecancermedicalscience; 2021; 15():1245. PubMed ID: 34267801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vortex keratopathy associated with ribociclib.
    Türkel A; Özdoğan S; Yekedüz E; Şeyran E; Karaçin C; Ateş Ö
    J Oncol Pharm Pract; 2023 Jan; 29(1):230-232. PubMed ID: 35570741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
    Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
    Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
    Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
    J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.